Study Achieves Primary and all Secondary Endpoints Demonstrating Clinically Meaningful, Statistically Significant Improvements in hrHPV Negativity at Week 12 as Compared to Placebo 46% of Patients ...
PARIS--(BUSINESS WIRE)--TheraVectys, a biotechnology company that designs and develops lentiviral vector-based vaccines and immunotherapies against infectious agents and cancers, announces that the ...
Background: Human papillomavirus (HPV)-associated anogenital warts have a prevalence of up to 78% in sexually active men. Some HPV subtypes bear a considerable oncogenic potential. Materials & methods ...
International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts We enrolled patients with HPV-related oropharyngeal carcinoma to receive ...
Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes—The Example of Bevacizumab in Epithelial Ovarian Cancer Three of nine patients experienced objective tumor responses (two ...
Previous trials have shown that a one-dose regimen of the HPV vaccine may be as effective as two- and three-dose regimens, “so it’s not surprising that we're seeing such high levels of what they're ...
Papillomas are noncancerous growths that can develop on your skin or mucous membranes. They rarely turn cancerous but can cause problems if they grow large and press on healthy tissue. Infection with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback